Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00828919 · ClinicalTrials.gov registry record · NA
Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials
A NA study, sponsored by Pfizer.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
NCT00828919 is a NA study that has completed, run by Pfizer. The registered enrollment target is 52 participants.
The verdict
NCT00828919, a NA study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
Study Summary
To allow continuation of axitinib (AG 013736) treatment to patients experiencing clinical benefit in a closing axitinib trial
Interventions
- DRUG axitinib
- DRUG crizotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2003-03-07 |
| Est. Completion | 2023-08-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00828919
The ClinicalTrials.gov registry entry for NCT00828919 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which axitinib is the first listed.
NCT00828919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00828919 about?
NCT00828919 is a clinical study titled "Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials". To allow continuation of axitinib (AG 013736) treatment to patients experiencing clinical benefit in a closing axitinib trial
What is the current status of trial NCT00828919?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2003-03-07. Estimated completion is 2023-08-14.
What interventions are being tested in trial NCT00828919?
The interventions under investigation include: axitinib (DRUG), crizotinib (DRUG).
Who is sponsoring clinical trial NCT00828919?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.